Table 2.
Multivariable linear regression models of the IIEF scores and subject characteristics
| Characteristic | Overall IIEF |
Erectile domain |
Orgasm domain |
Sexual desire |
Intercourse satisfaction |
Overall satisfaction |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | β (SE) | P-value | |
| Age (years) | ||||||||||||
| <30 | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| 30–39 | 3.37 (1.68) | .047∗ | 0.55 (0.83) | .51 | 0.64 (0.29) | .03∗ | 0.49 (0.31) | .12 | 0.92 (0.45) | .041∗ | 0.77 (0.38) | .042∗ |
| 40–49 | 2.91 (1.78) | .1 | 0.33 (0.87) | .71 | 0.74 (0.31) | .018∗ | 0.78 (0.33) | .019 | 0.39 (0.48) | .41 | 0.68 (0.4) | .09 |
| 50–59 | 1.91 (1.91) | .32 | 0.28 (0.94) | .76 | −0.07 (0.33) | .84 | 0.5 (0.35) | .16 | 0.35 (0.51) | .5 | 0.85 (0.43) | .047∗ |
| 60+ | 1.36 (1.83) | .46 | −1.13 (0.9) | .21 | 0 (0.32) | 1.00 | 0.76 (0.34) | .026∗ | 0.48 (0.49) | .33 | 1.25 (0.41) | .002∗∗ |
| Race | ||||||||||||
| White | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| Black/African | −0.68 (2.18) | .76 | −0.14 (1.07) | .9 | −1.06 (0.38) | .005 | −0.22 (0.4) | .59 | 0.64 (0.58) | .27 | 0.1 (0.49) | .84 |
| Hispanic/Latino | 0.54 (1.57) | .73 | −0.01 (0.77) | .99 | −0.14 (0.27) | .61 | 0.28 (0.29) | .34 | −0.14 (0.42) | .75 | 0.54 (0.35) | .13 |
| Other | −1.95 (1.72) | .26 | −0.37 (0.84) | .66 | −0.97 (0.3) | .001 | −0.11 (0.32) | .73 | −0.15 (0.46) | .75 | −0.35 (0.38) | .36 |
| Relationship status | ||||||||||||
| Married | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| In a relationship | −0.1 (1.34) | .94 | −0.14 (0.66) | .83 | −0.27 (0.23) | .24 | −0.28 (0.25) | .25 | 0.19 (0.36) | .59 | 0.4 (0.3) | .18 |
| Single | −3.65 (1.23) | .003∗∗ | −1.95 (0.6) | .001∗∗ | −0.39 (0.21) | .07 | 0.18 (0.23) | .43 | −0.13 (0.33) | .69 | −1.36 (0.27) | <.001∗∗∗ |
| Home region | ||||||||||||
| US West | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| International | −2.69 (1.69) | .11 | −1.13 (0.83) | .17 | −0.27 (0.29) | .35 | −0.32 (0.31) | .31 | −1.09 (0.45) | .016∗ | 0.13 (0.38) | .74 |
| US Midwest | −0.87 (1.81) | .63 | −0.35 (0.89) | .69 | 0.35 (0.31) | .27 | −0.23 (0.33) | .5 | −0.42 (0.48) | .38 | −0.22 (0.4) | .58 |
| US Northeast | −0.72 (1.41) | .61 | −0.06 (0.69) | .93 | −0.3 (0.25) | .22 | 0.1 (0.26) | .71 | −0.23 (0.38) | .54 | −0.22 (0.31) | .49 |
| US South | 0.54 (1.44) | .71 | −0.21 (0.71) | .77 | −0.06 (0.25) | .81 | −0.06 (0.27) | .82 | 0.56 (0.39) | .15 | 0.31 (0.32) | .33 |
| Tobacco smoking history | ||||||||||||
| Never smoker | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| Current smoker | −2.54 (1.57) | .11 | −1.06 (0.77) | .17 | −0.04 (0.27) | .88 | −0.54 (0.29) | .06 | −1.24 (0.42) | .003∗∗ | 0.34 (0.35) | .33 |
| Former smoker | −0.35 (1.12) | .76 | −0.1 (0.55) | .85 | 0.24 (0.19) | .22 | −0.43 (0.21) | .037∗ | −0.13 (0.3) | .65 | 0.08 (0.25) | .74 |
| # of PCP visits in the last 3 months | ||||||||||||
| 0 | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| 1 | −2.23 (1.14) | .05 | −1.01 (0.56) | .07 | −0.19 (0.2) | .35 | −0.23 (0.21) | .28 | −0.67 (0.3) | .029∗ | −0.14 (0.25) | .59 |
| 2+ | −3.96 (1.52) | .01∗ | −1.84 (0.74) | .014∗ | −0.71 (0.26) | .008∗∗ | −0.14 (0.28) | .61 | −0.76 (0.41) | .06 | −0.52 (0.34) | .13 |
| Total comorbidities | ||||||||||||
| 0 | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| 1 | −1.06 (1.29) | .41 | −0.38 (0.63) | .54 | −0.17 (0.22) | .45 | −0.24 (0.24) | .31 | −0.06 (0.34) | .86 | −0.2 (0.29) | .49 |
| 2 | −1.92 (1.45) | .19 | −0.39 (0.71) | .58 | −0.39 (0.25) | .12 | −0.43 (0.27) | .11 | −0.36 (0.39) | .36 | −0.35 (0.32) | .27 |
| 3+ | −2.32 (1.54) | .13 | −1.14 (0.75) | .13 | −0.04 (0.27) | .88 | −0.2 (0.28) | .48 | −0.57 (0.41) | .16 | −0.37 (0.34) | .28 |
| Cannabis use frequency (continuous)∗ | 0.74 (0.32) | .021∗ | 0.24 (0.16) | .12 | 0.1 (0.06) | .08 | 0.06 (0.06) | .34 | 0.17 (0.08) | .04∗ | 0.17 (0.07) | .018∗ |
| Cannabis chemovar | ||||||||||||
| THC dominant | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| CBD:THC 1:1 | −0.08 (1.16) | .94 | 0.03 (0.57) | .96 | −0.07 (0.2) | .72 | 0.16 (0.22) | .45 | −0.22 (0.31) | .48 | 0.02 (0.26) | .94 |
| CBD dominant | −1.73 (2.09) | .41 | −1.12 (1.02) | .27 | −0.01 (0.36) | .97 | 0.35 (0.39) | .37 | −1.35 (0.56) | .016 | 0.41 (0.47) | .38 |
| The primary method of consumption | ||||||||||||
| Smoking flower | Ref | Ref | Ref | Ref | Ref | Ref | ||||||
| Edibles | −2.16 (2.05) | .29 | −0.92 (1.01) | .36 | −0.3 (0.36) | .41 | −0.05 (0.38) | .9 | −0.62 (0.55) | .26 | −0.28 (0.46) | .55 |
| Smoking concentrates or extracts | −0.55 (1.86) | .77 | 0.18 (0.91) | .85 | −0.56 (0.32) | .09 | −0.2 (0.34) | .57 | −0.08 (0.5) | .87 | 0.11 (0.42) | .8 |
| Tincture or oils | 0.3 (2.1) | .88 | -0.39 (1.03) | .71 | 0.48 (0.36) | .19 | −0.31 (0.39) | .43 | 0.11 (0.56) | .85 | 0.41 (0.47) | .38 |
| Vaping | −1 (1.4) | .47 | −0.49 (0.69) | .48 | 0.06 (0.24) | .8 | −0.47 (0.26) | .07 | −0.35 (0.37) | .35 | 0.24 (0.31) | .43 |
| Other | −3.55 (2.79) | .2 | −1.27 (1.37) | .35 | −0.57 (0.48) | .24 | −0.79 (0.52) | .13 | −0.36 (0.74) | .63 | −0.56 (0.62) | .37 |
US = the United States; PCP = primary care physician; THC = tetrahydrocannabinol; CBD = cannabidiol; IIEF = International Index of Erectile Function.
∗P < .05, ∗∗P < .01, ∗∗∗P < .001.
∗
One-unit increase translates to one additional time using cannabis per week. Comorbidities assessed included hypertension, diabetes, heart disease, arthritis, lung disease, kidney disease, thyroid disease, hypercholesterolemia, cancer, neurologic disease, liver disease, depression, and anxiety.